Table 3. Hematologic toxicities.
| Patient # | PEG-LD (mg m−2) | No. of PEG-LD and valspodar cyclesa | ANC nadir mean (range) (cells μl−1) | Platelet nadir mean (range) (103 μl−1) | Haemoglobin mean (range) (g dl−1) |
|---|---|---|---|---|---|
| 1–14 | 20–25 | 0 | 3.803 (1.994–7.571) | 271 (161–424) | 11.2 (6.7–13.8) |
| 1 | 8 | 4b | 2.631 (1.613–3.602) | 220 (195–229) | 13.5 (12.8–14.1) |
| 2 | 16 | 13c | 3.106 (2.109–5.083) | 399 (295–529) | 12.1 (10.8–12.8) |
| 3–5 | 20 | 5 | 3.730 (2.275–6.255) | 311 (66–501) | 10.2 (8.3–12.5) |
| 6–8 | 22 | 17d | 2.826 (1.386–5.039) | 265 (113–464) | 11.0 (8.6–13.8) |
| 9–14 | 25 | 30e | 2.298 (0.936–7.056) | 298 (137–477) | 11.6 (8.7–14.0) |
a
Total number of cycles does not include cycle 1 (PEG-LD alone).
b
Patient #1 had dose escalations of 12, 16, and 20 mg m−2.
c
Patient #2 received dose escalations of 20 and 24 mg m−2 before dose reductions of 18 mg m−2 for five cycles and 13.5 mg m−2 for five cycles.
d
Patient #6 was dose reduced to 16.5 mg m−2 for four cycles and 12.4 mg m−2 for five cycles.
e
Patient #12 was dose reduced to 18.75 mg m−2 for five cycles and 14.06 mg m−2 for four cycles. Patient #14 was dose reduced to 18.75 mg m−2 for eight cycles.
PEG-LD=pegylated liposomal doxorubicin.